Evidence map›Paper›PMID 37505636›Full record

ArticleTropical medicine and infectious disease2023

Clinical Evolution and Risk Factors in Patients Infected during the First Wave of COVID-19: A Two-Year Longitudinal Study.

Carlos Rescalvo-Casas, Ramón Pérez-Tanoira, Rocío Fernández Villegas, Marcos Hernando-Gozalo, Laura Seijas-Pereda, Felipe Pérez-García, Helena Moza Moríñigo, Peña Gómez-Herruz, Teresa Arroyo, Rosa González and 4 more

Open access · goldAbstract read
In one paragraph

Article in Tropical medicine and infectious disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Carlos Rescalvo-CasasDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0003-3745-6661
Ramón Pérez-TanoiraDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0002-9816-3208
Rocío Fernández VillegasDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.
Marcos Hernando-GozaloDepartamento de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, 28805 Madrid, Spain.ORCID 0000-0003-2838-7270
Laura Seijas-PeredaDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0001-9360-7159
Felipe Pérez-GarcíaDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0002-4885-4334
Helena Moza MoríñigoDepartamento de Medicina Preventiva y Salud Pública, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain.
Peña Gómez-HerruzDepartamento de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, 28805 Madrid, Spain.
Teresa ArroyoDepartamento de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, 28805 Madrid, Spain.
Rosa GonzálezDepartamento de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, 28805 Madrid, Spain.
Cristina Verdú ExpósitoDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0002-3005-9244
Lourdes Lledó GarcíaDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0001-5387-6792
Juan Romanyk CabreraDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.ORCID 0000-0002-0067-1707
Juan Cuadros-GonzálezDepartamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad de Alcalá, 28805 Madrid, Spain.
Universidad de Alcalá · ESHospital Universitario Príncipe de Asturias · ESHospital Universitario Fundación Jiménez Díaz · ES

Funding

Community of Madrid with European Union funds against the COVID-19 pandemic DIABECOV-CM
6 · The paper itself

Abstract

A limited number of longitudinal studies have examined the symptoms associated with long-COVID-19. We conducted an assessment of symptom onset, severity and patient recovery, and determined the percentage of patients who experienced reinfection up to 2 years after the initial onset of the disease. Our cohort comprises 377 patients (≥18 years) with laboratory-confirmed COVID-19 in a secondary hospital (Madrid, Spain), throughout March 3-16, 2020. Disease outcomes and clinical data were followed-up until August 12, 2022. We reviewed the evolution of the 253 patients who had survived as of April 2020 (67.1%). Nine died between April 2020 and August 2022. A multivariate regression analysis performed to detect the risk factors associated with long-COVID-19 revealed that the increased likelihood was associated with chronic obstructive lung disease (OR 14.35, 95% CI 1.89-109.09;

Indexed as

coronavirus disease 2019long-COVID-19reinfectionrisk factorsSARS-CoV-2vaccines

Identifiers

PMID37505636
PMCPMC10384910
OpenAlexW4382134216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.